• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pharming Group to participate in March investor conference

    2/28/25 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAR alert in real time by email

    Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of March:

    • 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025

      Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET.

    For more information about this conference, or to schedule a one-to-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at [email protected] or your Roth representative.

    About Pharming Group N.V.

    Pharming Group N.V. (NASDAQ:PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

    For more information, visit www.pharming.com and find us on LinkedIn.

    For further public information, contact:

    Pharming Group, Leiden, the Netherlands

    Michael Levitan, VP Investor Relations & Corporate Communications

    T: +1 (908) 705 1696

    E: [email protected]

    FTI Consulting, London, United Kingdom

    Simon Conway/Alex Shaw/Amy Byrne

    T: +44 203 727 1000

    LifeSpring Life Sciences Communication, Amsterdam, the Netherlands

    Leon Melens

    T: +31 6 53 81 64 27

    E: [email protected]

    Attachment

    • Pharming attending Investor Conferences March 2025_EN_28FEB25


    Primary Logo

    Get the next $PHAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAR

    DatePrice TargetRatingAnalyst
    12/9/2024$14.00Buy
    Jefferies
    More analyst ratings

    $PHAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Pharming Group N.V. with a new price target

      Jefferies initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $14.00

      12/9/24 8:05:53 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care